Dr Thomas Mulroney studied Biochemistry at the University of Birmingham in 2016. He joined Prof. Anne Willis’ lab at the MRC Toxicology Unit and Dr Ann Doherty’s team at AstraZeneca to investigate modified nucleosides in antisense oligonucleotides and in vitro transcribed messenger RNAs, obtaining his PhD from Jesus College, Cambridge in 2021. He has worked as a postdoctoral research associate at the MRC Toxicology Unit, University of Cambridge and a senior research associate at the Engineering Science Department at University of Oxford, investigating mRNA translation, RNA-based therapeutics, and engineering biology tools for protein and RNA detection. Dr Mulroney is a research fellow in the Department of Physiology, Anatomy and Genetics and the Institute of Developmental and Regenerative Medicine (University of Oxford). His research investigates the design, synthesis, and evaluation of nucleic acid therapeutics for treating cardiovascular diseases, supported by the British Heart Foundation and the Medical Research Council.